HRP20200661T1 - Razine ceramida u liječenju i prevenciji infekcija - Google Patents
Razine ceramida u liječenju i prevenciji infekcija Download PDFInfo
- Publication number
- HRP20200661T1 HRP20200661T1 HRP20200661TT HRP20200661T HRP20200661T1 HR P20200661 T1 HRP20200661 T1 HR P20200661T1 HR P20200661T T HRP20200661T T HR P20200661TT HR P20200661 T HRP20200661 T HR P20200661T HR P20200661 T1 HRP20200661 T1 HR P20200661T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid ceramidase
- use according
- subject
- ceramide
- acid
- Prior art date
Links
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims 7
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims 7
- 229940106189 ceramide Drugs 0.000 title claims 7
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims 7
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims 7
- 208000015181 infectious disease Diseases 0.000 title claims 5
- 230000002265 prevention Effects 0.000 title 1
- 102000006772 Acid Ceramidase Human genes 0.000 claims 19
- 108020005296 Acid Ceramidase Proteins 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 210000003097 mucus Anatomy 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000001533 respiratory mucosa Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Kisela ceramidaza za uporabu u postupku za liječenje ili sprečavanje bakterijskih infekcija kod subjekta koji ima cističnu fibrozu, navedeni postupak sadrži:
odabir subjekta koji ima cističnu fibrozu i
davanje navedenom odabranom subjektu kisele ceramidaze u uvjetima koji su učinkoviti za smanjenje ceramida i
za liječenje ili sprečavanje navedene bakterijske infekcije u navedenom odabranom subjektu.
2. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što je subjekt odabran na temelju povišene razine ceramida u usporedbi s referentnom razinom za subjekta koji nema spomenutu cističnu fibrozu.
3. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se navedeni odabir temelji na razini ceramida u plućnom epitelu, nazalnom epitelu, sluzi i / ili stanicama izoliranim sa mjesta otvorene rane.
4. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se navedeno davanje provodi u uvjetima koji su učinkoviti za normalizaciju razina ceramida u respiratornom epitelu, sluzi ili stanicama subjekta na mjestu otvorene rane.
5. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se jedno ili više dodatnih sredstava koja smanjuju razine ceramida daju u kombinaciji s navedenom kiselom ceramidazom.
6. Kisela ceramidaza za uporabu prema zahtjevu 5, naznačena time što je navedeno jedno ili više dodatnih sredstava odabrano iz skupine koja se sastoji od jednog ili više dodatnih sredstava za smanjenje ceramida, jednog ili više inhibitora kisele sfingomijelinaze, jednog ili više sredstva za smanjenje infekcije i njihovih kombinacija.
7. Kisela ceramidaza za uporabu prema zahtjevu 6, naznačena time što navedeno jedno ili više dodatnih sredstava je jedno ili više sredstava za smanjenje infekcije i odabrano je iz skupine koja se sastoji od antibiotika, reagensa koji blokiraju vezanje patogena na epitel pluća, reagensa za smanjenje viskoznosti sluzi, pratećih reagensa za poboljšanje funkcije proteina koji nedostaju, i njihove kombinacije.
8. Kisela ceramidaza za uporabu prema zahtjevu 6, naznačena time što se navedena kisela ceramidaza daje istovremeno, odvojeno, ili uzastopno s navedenim jednim ili više dodatnih sredstava.
9. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što je navedeno davanje oralno, topikalno, intranazalno, intraperitonealno, intravensko, subkutano ili inhalacijom aerosola.
10. Kisela ceramidaza za uporabu prema zahtjevu 9, naznačena time što je navedeno davanje aerosolnom inhalacijom.
11. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se kisela ceramidaza daje u količini od 0.001 mg / kg do 500 mg / kg.
12. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se navedena kisela ceramidaza daje prije početka infekcije.
13. Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se navedena kisela ceramidaza daje nakon početka infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654519P | 2012-06-01 | 2012-06-01 | |
| PCT/US2013/043608 WO2013181530A1 (en) | 2012-06-01 | 2013-05-31 | Ceramide levels in the treatment and prevention of infections |
| EP13797635.3A EP2854910B1 (en) | 2012-06-01 | 2013-05-31 | Ceramide levels in the treatment and prevention of infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200661T1 true HRP20200661T1 (hr) | 2020-10-30 |
Family
ID=49673925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200661TT HRP20200661T1 (hr) | 2012-06-01 | 2020-04-24 | Razine ceramida u liječenju i prevenciji infekcija |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9492514B2 (hr) |
| EP (2) | EP3679923B1 (hr) |
| JP (4) | JP6369814B2 (hr) |
| CN (2) | CN109529028A (hr) |
| CA (1) | CA2874146C (hr) |
| DK (1) | DK2854910T3 (hr) |
| ES (2) | ES2897825T3 (hr) |
| HR (1) | HRP20200661T1 (hr) |
| HU (1) | HUE051020T2 (hr) |
| LT (1) | LT2854910T (hr) |
| PL (1) | PL2854910T3 (hr) |
| PT (1) | PT2854910T (hr) |
| SI (1) | SI2854910T1 (hr) |
| WO (1) | WO2013181530A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 |
| HUE051021T2 (hu) | 2011-09-07 | 2021-01-28 | Sinai School Medicine | Ceramidáz és sejtek differenciálódása |
| EP3679923B1 (en) * | 2012-06-01 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Ceramide levels in the treatment and prevention of infections |
| HUE046113T2 (hu) * | 2013-03-14 | 2020-02-28 | Icahn School Med Mount Sinai | Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai |
| ES2673276T3 (es) | 2013-03-14 | 2018-06-21 | University Of Ottawa | Métodos para el diagnóstico y el tratamiento de la enfermedad inflamatoria intestinal |
| CA2962802A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Ottawa | Markers for inflammatory bowel disease |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| EP3568154B1 (en) * | 2017-01-13 | 2023-07-12 | Icahn School of Medicine at Mount Sinai | Compositions and methods for treating farber disease |
| WO2022190064A1 (en) * | 2021-03-12 | 2022-09-15 | Vexo Pharmaceuticals Dmcc | Methods for identifying subjects with betacoronavirus infections who are at risk of acute respiratory syndrome and methods for the treatment of same |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| CH585793A5 (hr) | 1974-02-01 | 1977-03-15 | Nestle Sa | |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| JPS5322158B2 (hr) | 1974-05-02 | 1978-07-06 | ||
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| IT1130242B (it) | 1980-02-01 | 1986-06-11 | Anic Spa | Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0463109A4 (en) | 1989-03-24 | 1992-11-19 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| US5382524A (en) | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1994015578A1 (en) | 1992-12-30 | 1994-07-21 | George Joe Revis | Anticaries compositions |
| EP0706374B1 (en) | 1993-06-30 | 1997-12-10 | Genentech, Inc. | Method for preparing liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| DE69835367T2 (de) | 1997-10-29 | 2007-08-02 | Genzyme Corp., Framingham | Gentherapie für gaucher-krankheit |
| JP2002506046A (ja) | 1998-03-10 | 2002-02-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 薬剤および遺伝子の細胞内送達および組織標的化の促進 |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US7018628B1 (en) | 1998-07-24 | 2006-03-28 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| US6258581B1 (en) | 1998-08-20 | 2001-07-10 | Takara Shuzo Co., Ltd. | Ceramidase gene |
| GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| US6767741B1 (en) | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| JP2003516122A (ja) | 1999-10-13 | 2003-05-13 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ｄａｐキナーゼのショートセグメント |
| US6350768B1 (en) | 1999-11-24 | 2002-02-26 | Aventis Pharma S.A. | Combination of riluzole and of gabapentin and its use as a medicament |
| US7850984B2 (en) | 2000-02-15 | 2010-12-14 | The General Hospital Corporation | Protection of the female reproductive system from natural and artificial insults |
| IL152110A0 (en) | 2000-04-06 | 2003-07-31 | Exegenics Inc | Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase) |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| ES2523856T3 (es) | 2000-12-22 | 2014-12-02 | Lpath, Inc. | Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos |
| US20020142299A1 (en) | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
| EP1234816B1 (de) | 2001-02-23 | 2004-06-30 | Biofrontera Pharmaceuticals GmbH | Scyphostatin-Analoga als SMase-Inhibitoren |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| EP1478734A4 (en) | 2002-01-25 | 2006-04-05 | Genzyme Corp | NON-SERUM MEDIUM FOR CHONDROCYTES AND METHODS OF USE THEREOF |
| US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| DE10239531A1 (de) * | 2002-08-23 | 2004-03-04 | Gulbins, Erich, Prof. Dr. | Prophylaxe und Therapie von Infektionserkrankungen |
| EP1431399A1 (en) | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| EP1649064B1 (en) | 2003-07-17 | 2011-06-01 | Pacific Edge Biotechnology Limited | Markers for detection of gastric cancer |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| US8017394B2 (en) | 2004-10-01 | 2011-09-13 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| US7273756B2 (en) | 2004-10-01 | 2007-09-25 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| CA2585645C (en) | 2004-10-29 | 2014-10-21 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
| US7993868B2 (en) | 2005-04-19 | 2011-08-09 | Vermillion, Inc. | Saposin D and FAM3C are biomarkers for alzheimer's disease |
| CN101282733A (zh) * | 2005-08-03 | 2008-10-08 | 莫里亚生物制药公司 | 脂质结合物在囊性纤维化病中的用途及其应用 |
| US7981399B2 (en) | 2006-01-09 | 2011-07-19 | Mcgill University | Method to determine state of a cell exchanging metabolites with a fluid medium by analyzing the metabolites in the fluid medium |
| EP1994408A4 (en) | 2006-01-27 | 2009-05-06 | Eastern Virginia Med School | PROTEOMIC FINGERPRINTS OF IVF-HUMAN EMBRYOS: IDENTIFICATION OF BIOMARKERS OF DEVELOPMENT POTENTIAL |
| WO2007095688A1 (en) | 2006-02-23 | 2007-08-30 | The Australian National University | Methods for increasing the number of circulating cells |
| JP2009538276A (ja) * | 2006-04-24 | 2009-11-05 | アカデミッシュ メディシュ セントラム | 嚢胞性線維症の改良型治療 |
| WO2007136635A1 (en) | 2006-05-16 | 2007-11-29 | Musc Foundation For Research Development | Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators |
| EP2924440A3 (en) | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| CN101490245B (zh) | 2006-06-20 | 2013-01-16 | 建新公司 | 无血清培养基及其在软骨细胞扩增中的用途 |
| CA2674849A1 (en) * | 2007-01-05 | 2008-07-17 | Mount Sinai School Of Medicine | Acid ceramidase and cell survival |
| EP2132562B9 (en) | 2007-04-06 | 2012-05-23 | Genzyme Corporation | Methods of evaluating cells and cell cultures |
| US8956825B2 (en) | 2007-05-24 | 2015-02-17 | The United States Of America As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
| AU2008255565B2 (en) | 2007-05-31 | 2013-10-24 | Paradigm Biopharmaceuticals Ltd | Sulphated xylans for treatment or prophylaxis of respiratory diseases |
| FR2924946B1 (fr) | 2007-12-18 | 2010-02-26 | Oreal | Utilisation cosmetique de proteines de type ceramidase acide |
| DE102007063535A1 (de) * | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
| CA3004867C (en) | 2008-06-26 | 2020-09-15 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| US8697379B2 (en) * | 2008-11-06 | 2014-04-15 | Musc Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
| US20120115158A1 (en) | 2009-05-01 | 2012-05-10 | Mount Sinai School Of Medicine | Method to determine embryo and oocyte quality based on ceramidase |
| LT3482767T (lt) | 2009-08-28 | 2022-01-10 | Icahn School Of Medicine At Mount Sinai | Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti |
| CA2778349C (en) | 2009-10-19 | 2018-12-04 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| SI2796457T1 (sl) | 2009-11-27 | 2016-10-28 | Genzyme Corporation | Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji |
| WO2012051415A2 (en) | 2010-10-13 | 2012-04-19 | Mount Sinai School Of Medicine | Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
| WO2013101276A2 (en) | 2011-04-01 | 2013-07-04 | Mount Sinai School Of Medicine | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway |
| EP2707724A4 (en) | 2011-05-10 | 2015-01-21 | Advanced Liquid Logic Inc | ENZYME CONCENTRATION AND ASSAYS FOR THIS |
| EP2721151B1 (en) | 2011-06-20 | 2017-12-06 | Mount Sinai School Of Medicine | Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders |
| HUE051021T2 (hu) | 2011-09-07 | 2021-01-28 | Sinai School Medicine | Ceramidáz és sejtek differenciálódása |
| EP3679923B1 (en) | 2012-06-01 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Ceramide levels in the treatment and prevention of infections |
| HUE046113T2 (hu) | 2013-03-14 | 2020-02-28 | Icahn School Med Mount Sinai | Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai |
-
2013
- 2013-05-31 EP EP20161022.7A patent/EP3679923B1/en active Active
- 2013-05-31 CN CN201811635845.2A patent/CN109529028A/zh active Pending
- 2013-05-31 JP JP2015515238A patent/JP6369814B2/ja active Active
- 2013-05-31 ES ES20161022T patent/ES2897825T3/es active Active
- 2013-05-31 CA CA2874146A patent/CA2874146C/en active Active
- 2013-05-31 US US14/404,881 patent/US9492514B2/en active Active
- 2013-05-31 WO PCT/US2013/043608 patent/WO2013181530A1/en active Application Filing
- 2013-05-31 LT LTEP13797635.3T patent/LT2854910T/lt unknown
- 2013-05-31 DK DK13797635.3T patent/DK2854910T3/da active
- 2013-05-31 PT PT137976353T patent/PT2854910T/pt unknown
- 2013-05-31 PL PL13797635T patent/PL2854910T3/pl unknown
- 2013-05-31 SI SI201331715T patent/SI2854910T1/sl unknown
- 2013-05-31 ES ES13797635T patent/ES2786128T3/es active Active
- 2013-05-31 CN CN201380031825.3A patent/CN104582770B/zh active Active
- 2013-05-31 HU HUE13797635A patent/HUE051020T2/hu unknown
- 2013-05-31 EP EP13797635.3A patent/EP2854910B1/en active Active
-
2016
- 2016-10-05 US US15/286,327 patent/US10159724B2/en active Active
-
2018
- 2018-07-02 JP JP2018125882A patent/JP6639574B2/ja active Active
- 2018-11-15 US US16/192,241 patent/US20190151424A1/en not_active Abandoned
-
2019
- 2019-12-24 JP JP2019232581A patent/JP2020050668A/ja active Pending
-
2020
- 2020-04-24 HR HRP20200661TT patent/HRP20200661T1/hr unknown
-
2021
- 2021-08-09 US US17/397,298 patent/US20220202919A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199280A patent/JP2023021305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020050668A (ja) | 2020-04-02 |
| JP2015518054A (ja) | 2015-06-25 |
| US10159724B2 (en) | 2018-12-25 |
| CN104582770B (zh) | 2019-01-29 |
| EP2854910B1 (en) | 2020-04-15 |
| US9492514B2 (en) | 2016-11-15 |
| US20150125439A1 (en) | 2015-05-07 |
| JP6369814B2 (ja) | 2018-08-08 |
| JP2018162303A (ja) | 2018-10-18 |
| EP2854910A1 (en) | 2015-04-08 |
| EP3679923B1 (en) | 2021-08-04 |
| EP2854910A4 (en) | 2016-02-24 |
| SI2854910T1 (sl) | 2020-09-30 |
| CN109529028A (zh) | 2019-03-29 |
| EP3679923A1 (en) | 2020-07-15 |
| WO2013181530A1 (en) | 2013-12-05 |
| US20170020998A1 (en) | 2017-01-26 |
| HUE051020T2 (hu) | 2021-01-28 |
| CA2874146C (en) | 2023-03-21 |
| PL2854910T3 (pl) | 2020-07-27 |
| ES2786128T3 (es) | 2020-10-08 |
| US20220202919A1 (en) | 2022-06-30 |
| US20190151424A1 (en) | 2019-05-23 |
| DK2854910T3 (da) | 2020-05-04 |
| LT2854910T (lt) | 2020-05-25 |
| JP6639574B2 (ja) | 2020-02-05 |
| PT2854910T (pt) | 2020-05-06 |
| ES2897825T3 (es) | 2022-03-02 |
| CN104582770A (zh) | 2015-04-29 |
| JP2023021305A (ja) | 2023-02-10 |
| CA2874146A1 (en) | 2013-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200661T1 (hr) | Razine ceramida u liječenju i prevenciji infekcija | |
| MX2019006938A (es) | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. | |
| MX346244B (es) | Composiciones de vancomicina en polvo seco y metodos asociados. | |
| BR112016026699A8 (pt) | uso de amicacina ou de um sal farmaceuticamente aceitável desta | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
| CA2897464C (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| WO2011141929A3 (en) | Aqueous pharmaceutical compositions of fluticasone and olopatadine | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| EA201590933A1 (ru) | Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования | |
| BR112015028964A2 (pt) | composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar | |
| WO2007098106A3 (en) | Respiratory tract delivery of interferon-tau | |
| WO2014018668A3 (en) | Aerosol pirfenidone and pyridone analog compounds | |
| MD4369C1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| HRP20160328T1 (hr) | Tritokvalin za uporabu u liječenju cistične fibroze | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| BR112014005538A2 (pt) | composições aquosas compreendendo arbecacina | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| EP4114393A4 (en) | METHOD FOR TREATING AND PREVENTING LUNG INFECTIONS BY ADMINISTRATING TAFENOCHIN | |
| MX2020010977A (es) | Procedimientos de tratamiento de infecciones fúngicas. | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| WO2018065917A3 (en) | A synthetic pulmonary surfactant composition for treating lung conditions | |
| WO2015066664A3 (en) | Compositions and methods for administration of an enzyme to a subject's airway | |
| WO2014159917A3 (en) | Treatment for exposure to nerve agent |